Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Predicting Response or Non-response to Urate-Lowering Therapy in Patients with Gout.

Graham GG, Stocker SL, Kannangara DRW, Day RO.

Curr Rheumatol Rep. 2018 Jun 21;20(8):47. doi: 10.1007/s11926-018-0760-2. Review.

PMID:
29931553
2.

Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study.

Counsell AB, Nguyen AD, Baysari MT, Kannangara DRW, McLachlan AJ, Day RO.

BMC Fam Pract. 2018 May 9;19(1):54. doi: 10.1186/s12875-018-0744-3.

3.

Individualising the dose of allopurinol in patients with gout.

Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO.

Br J Clin Pharmacol. 2017 Sep;83(9):2015-2026. doi: 10.1111/bcp.13307. Epub 2017 May 28.

4.

Allopurinol: insights from studies of dose-response relationships.

Day RO, Kannangara DR, Stocker SL, Carland JE, Williams KM, Graham GG.

Expert Opin Drug Metab Toxicol. 2017 Apr;13(4):449-462. doi: 10.1080/17425255.2017.1269745. Epub 2016 Dec 20. Review.

PMID:
27927043
5.

Xanthine oxidoreductase and its inhibitors: relevance for gout.

Day RO, Kamel B, Kannangara DR, Williams KM, Graham GG.

Clin Sci (Lond). 2016 Dec 1;130(23):2167-2180. Review.

PMID:
27798228
6.

Mobile applications to enhance self-management of gout.

Nguyen AD, Baysari MT, Kannangara DR, Tariq A, Lau AY, Westbrook JI, Day RO.

Int J Med Inform. 2016 Oct;94:67-74. doi: 10.1016/j.ijmedinf.2016.06.021. Epub 2016 Jun 30.

PMID:
27573313
7.

Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate.

Kannangara DR, Phipps-Green AJ, Dalbeth N, Stamp LK, Williams KM, Graham GG, Day RO, Merriman TR.

Ann Rheum Dis. 2016 Jul;75(7):1363-6. doi: 10.1136/annrheumdis-2015-208111. Epub 2015 Dec 1.

PMID:
26835700
8.

Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine.

Kannangara DR, Graham GG, Williams KM, Day RO.

Clin Rheumatol. 2016 Sep;35(9):2375-6. doi: 10.1007/s10067-015-3165-x. Epub 2016 Jan 7. No abstract available.

PMID:
26742757
9.

Barriers to Care in Gout: From Prescriber to Patient.

Vaccher S, Kannangara DR, Baysari MT, Reath J, Zwar N, Williams KM, Day RO.

J Rheumatol. 2016 Jan;43(1):144-9. doi: 10.3899/jrheum.150607. Epub 2015 Nov 15.

PMID:
26568590
10.

Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout.

McKinney C, Stamp LK, Dalbeth N, Topless RK, Day RO, Kannangara DR, Williams KM, Janssen M, Jansen TL, Joosten LA, Radstake TR, Riches PL, Tausche AK, Lioté F, So A, Merriman TR.

Arthritis Res Ther. 2015 Oct 13;17:288. doi: 10.1186/s13075-015-0802-3.

11.

Understanding and improving the use of allopurinol in a teaching hospital.

Hmar RC, Kannangara DR, Ramasamy SN, Baysari MT, Williams KM, Day RO.

Intern Med J. 2015 Apr;45(4):383-90. doi: 10.1111/imj.12701.

PMID:
25644128
12.

An audit of a therapeutic drug monitoring service for allopurinol therapy.

Kannangara DR, Ramasamy SN, Ray JE, Jones G, Graham GG, Williams KM, Day RO.

Ther Drug Monit. 2013 Dec;35(6):863-6. doi: 10.1097/FTD.0b013e318299920a.

PMID:
24263644
13.

Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Ramasamy SN, Korb-Wells CS, Kannangara DR, Smith MW, Wang N, Roberts DM, Graham GG, Williams KM, Day RO.

Drug Saf. 2013 Oct;36(10):953-80. doi: 10.1007/s40264-013-0084-0. Review.

PMID:
23873481
14.

Hypouricemic effects of prednisone and allopurinol: an uneven playing field?

Kannangara DR, Graham GG, Williams KM, Day RO.

Can J Cardiol. 2014 Mar;30(3):376.e1. doi: 10.1016/j.cjca.2013.04.015. Epub 2013 Jul 4. No abstract available.

PMID:
23831009
15.

Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.

Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO.

Br J Clin Pharmacol. 2013 Dec;76(6):932-8. doi: 10.1111/bcp.12126.

16.

Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.

Kannangara DR, Ramasamy SN, Indraratna PL, Stocker SL, Graham GG, Jones G, Portek I, Williams KM, Day RO.

Arthritis Res Ther. 2012 Aug 17;14(4):R189. doi: 10.1186/ar4020.

17.

Successful use of allopurinol in a patient on dialysis.

Day RO, Kannangara DR, Hayes JM, Furlong TJ.

BMJ Case Rep. 2012 Jun 5;2012. pii: bcr0220125814. doi: 10.1136/bcr.02.2012.5814.

18.

Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.

Kannangara DR, Roberts DM, Furlong TJ, Graham GG, Williams KM, Day RO.

Br J Clin Pharmacol. 2012 May;73(5):828-9. doi: 10.1111/j.1365-2125.2011.04147.x. No abstract available.

Supplemental Content

Loading ...
Support Center